Endocrinology
Conditions
Interventions
A group:HbA1c(5.5-6.49%)
B group:HbA1c(6.5-6.99%)
C group:HbA1c(7.0-7.49%)
D group:HbA1c(7.5-7.99%)
E group:HbA1c(8.0-8.5%)
Sponsors
Tianjin Metabolic Diseases Hospital, Tianjin Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: For eligible subjects, all inclusion criteria must be "yes" 1. Signed informed consent; 2. Aged 18 to 70 years old, male or female; 3. Suffering from type 2 diabetes (clinical diagnosis) more than 12 months; 4. Blood glucose control was stable. The difference of HbA1c was less than 1% and HbA1c was 5.5-8.5% within 6 months before screening. 5. body mass index 18.5 to 35 kg/m2; 6. Patients are willing to adhere to research programs, including multiple self-blood glucose (SMBG), dynamic blood glucose monitoring (CGM) and biochemical tests; 7. On the basis of the original treatment (diet, exercise, oral medication, insulin or insulin pump), the doctor adjust the treatment programin in accordance with the patient's condition, so that HbA1c maintains between 5.5-8.5%;Inclusion criteria: For eligible subjects, all inclusion criteria must be "yes" 1. Signed informed consent; 2. Aged 18 to 70 years old, male or female; 3. Suffering from type 2 diabetes (clinical diagnosis) more than 12 months; 4. Blood glucose control was stable. The difference of HbA1c was less than 1% and HbA1c was 5.5-8.5% within 6 months before screening. 5. body mass index 18.5 to 35 kg/m2; 6. Patients are willing to adhere to research programs, including multiple self-blood glucose (SMBG), dynamic blood glucose monitoring (CGM) and biochemical tests; 7. On the basis of the original treatment (diet, exercise, oral medication, insulin or insulin pump), the doctor adjust the treatment programin in accordance with the patient's condition, so that HbA1c maintains between 5.5-8.5%;Inclusion criteria: For eligible subjects, all inclusion criteria must be "yes" 1. Signed informed consent; 2. Aged 18 to 70 years old, male or female; 3. Suffering from type 2 diabetes (clinical diagnosis) more than 12 months; 4. Blood glucose control was stable. The difference of HbA1c was less than 1% and HbA1c was 5.5-8.5% within 6 months before screening. 5. body mass index 18.5 to 35 kg/m2; 6. Patients are willing to adhere to research programs, including multiple self-blood glucose (SMBG), dynamic blood glucose monitoring (CGM) and biochemical tests; 7. On the basis of the original treatment (diet, exercise, oral medication, insulin or insulin pump), the doctor adjust the treatment programin in accordance with the patient's condition, so that HbA1c maintains between 5.5-8.5%;Inclusion criteria: For eligible subjects, all inclusion criteria must be "yes" 1. Signed informed consent; 2. Aged 18 to 70 years old, male or female; 3. Suffering from type 2 diabetes (clinical diagnosis) more than 12 months; 4. Blood glucose control was stable. The difference of HbA1c was less than 1% and HbA1c was 5.5-8.5% within 6 months before screening. 5. body mass index 18.5 to 35 kg/m2; 6. Patients are willing to adhere to research programs, including multiple self-blood glucose (SMBG), dynamic blood glucose monitoring (CGM) and biochemical tests; 7. On the basis of the original treatment (diet, exercise, oral medication, insulin or insulin pump), the doctor adjust the treatment programin in accordance with the patient's condition, so that HbA1c maintains between 5.5-8.5%;Inclusion criteria: For eligible subjects, all inclusion criteria must be "yes" 1. Signed informed consent; 2. Aged 18 to 70 years old, male or female; 3. Suffering from type 2 diabetes (clinical diagnosis) more than 12 months; 4. Blood glucose control was stable. The difference of HbA1c was less than 1% and HbA1c was 5.5-8.5% within 6 months before screening. 5. body mass index 18.5 to 35 kg/m2; 6. Patients are willing to adhere to research programs, including multiple self-blood glucose (SMBG), dynamic blood glucose monitoring (CGM) and biochemical tests; 7. On the basis of the original treatment (diet, exercise, oral medication, insulin or insulin pump), the doctor adjust the treatment programin in accordance with the patient's condition, so that HbA1c maintains between 5.5-8.5%
Exclusion criteria
Exclusion criteria: For eligible subjects, all negative criteria must be "no" 1. Fertility of women in pregnancy, lactation or planned pregnancy or did not take adequate contraceptive measures (sterilization, intrauterine contraceptives, oral contraceptives); 2. There may be any significant changes in blood glucose during the trial, such as hormone therapy, infection, surgery or trauma; 3. There may be any disease or treatment may affect HbA1c and average blood glucose, such as anemia (hematocrit, male <39%, female <36%), high erythrocyte turnover (reticulosis), blood loss or Blood transfusion, chronic kidney or liver disease, high-dose vitamin C or erythropoietin treatment; 4. A subject judged by a researcher who is mentally retarded, unwilling or unable to fully understand or cooperate due to speech disorder; 5. Any other circumstances judged by the investigator that may endanger the safety of the subject and affect program compliance or test results.;Exclusion criteria: For eligible subjects, all negative criteria must be "no" 1. Fertility of women in pregnancy, lactation or planned pregnancy or did not take adequate contraceptive measures (sterilization, intrauterine contraceptives, oral contraceptives); 2. There may be any significant changes in blood glucose during the trial, such as hormone therapy, infection, surgery or trauma; 3. There may be any disease or treatment may affect HbA1c and average blood glucose, such as anemia (hematocrit, male <39%, female <36%), high erythrocyte turnover (reticulosis), blood loss or Blood transfusion, chronic kidney or liver disease, high-dose vitamin C or erythropoietin treatment; 4. A subject judged by a researcher who is mentally retarded, unwilling or unable to fully understand or cooperate due to speech disorder; 5. Any other circumstances judged by the investigator that may endanger the safety of the subject and affect program compliance or test results.;Exclusion criteria: For eligible subjects, all negative criteria must be "no" 1. Fertility of women in pregnancy, lactation or planned pregnancy or did not take adequate contraceptive measures (sterilization, intrauterine contraceptives, oral contraceptives); 2. There may be any significant changes in blood glucose during the trial, such as hormone therapy, infection, surgery or trauma; 3. There may be any disease or treatment may affect HbA1c and average blood glucose, such as anemia (hematocrit, male <39%, female <36%), high erythrocyte turnover (reticulosis), blood loss or Blood transfusion, chronic kidney or liver disease, high-dose vitamin C or erythropoietin treatment; 4. A subject judged by a researcher who is mentally retarded, unwilling or unable to fully understand or cooperate due to speech disorder; 5. Any other circumstances judged by the investigator that may endanger the safety of the subject and affect program compliance or test results.;Exclusion criteria: For eligible subjects, all negative criteria must be "no" 1. Fertility of women in pregnancy, lactation or planned pregnancy or did not take adequate contraceptive measures (sterilization, intrauterine contraceptives, oral contraceptives); 2. There may be any significant changes in blood glucose during the trial, such as hormone therapy, infection, surgery or trauma; 3. There may be any disease or treatment may affect HbA1c and average blood glucose, such as anemia (hematocrit, male <39%, female <36%), high erythrocyte turnover (reticulosis), blood loss or Blood transfusion, chronic kidney or liver disease, high-dose vitamin C or erythropoietin treatment; 4. A subject judged by a researcher who is mentally retarded, unwilling or unable to fully understand or cooperate due to speech disorder; 5. Any other circumstances judged by the investigator that may endanger the safety of the subject and affect program compliance or test results.;Exclusion criteria: For eligible subjects, all negative criteria must be "no" 1. Fertility of women in pregnancy, lactation or planned pregnancy or did not take adequate contraceptive measures (sterilization, intrauterine contraceptives, oral contraceptives); 2. There may be any significant changes in blood glucose during the trial, such as hormone therapy, infection, surgery or trauma; 3. There may be any disease or treatment may affect HbA1c and average blood glucose, such as anemia (hematocrit, male <39%, female <36%), high erythrocyte turnover (reticulosis), blood loss or Blood transfusion, chronic kidney or liver disease, high-dose vitamin C or erythropoietin treatment; 4. A subject judged by a researcher who is mentally retarded, unwilling or unable to fully understand or cooperate due to speech disorder; 5. Any other circumstances judged by the investigator that may endanger the safety of the subject and affect program compliance or test results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting blood glucose;preprandial blood glucose;Postprandial blood glucose;Bedtime blood glucose;Three o 'clock blood glucose;HbA1c; | — |
Countries
China
Contacts
Public ContactChen Liming;Chen Liming;Chen Liming;Chen Liming;Chen Liming ;;;;
Tianjin Metabolic Diseases Hospital, Tianjin Medical University;Tianjin Metabolic Diseases Hospital, Tianjin Medical University;Tianjin Metabolic Diseases Hospital, Tianjin Medical University;Tianjin Metabolic Diseases Hospital, Tianjin Medical University;Tianjin Metabolic Diseases Hospital, Tianjin Medical University
Outcome results
None listed